Antiphospholipid syndrome: Autoimmunity and thrombosis

Kumar, Pasupuleti Kishore and Ruchitha, Thokala and Varun, Pasumala and Kumar, Chinta Rohit and Rao, Tadikonda Rama (2025) Antiphospholipid syndrome: Autoimmunity and thrombosis. World Journal of Biology Pharmacy and Health Sciences, 22 (3). pp. 602-605. ISSN 2582-5542

The rare systemic autoimmune disease known as antiphospholipid syndrome (APS) is typified by persistent antiphospholipid antibodies (aPL) along with obstetric morbidity, recurrent thrombosis in the veins and/or arteries, and other non-thrombotic related complications. Obesity, diabetes, hypertension, and cardiovascular diseases are among the long-term health problems that children from difficult pregnancies may be more susceptible to, which could impact their wellbeing both during childhood and into adulthood. Antiphospholipid antibodies' precise etiology is unknown. Being an autoimmune disease, APS causes antibodies to target healthy molecules such as phospholipids, which interferes with coagulation and makes the patient more prone to thrombophilia. The cornerstones of the current preventative treatment standard for APS are anticoagulation and antiplatelet therapy. One significant preventable cause of early pregnancy loss is APS. Preventing obstetric complications requires early risk assessment and individualized treatment, which may include vitamin D, folic acid, and aspirin.